Drug intelligence / Profile preview

Monorova + Amlopin

Development stage
Unknown
Modality
Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration
Oral
01

Overview

Monorova + Amlopin is a fixed-dose combination medication used for the treatment of hypertension (high blood pressure). It contains two active pharmaceutical ingredients: - Monorova, which is a brand name for atenolol, a beta-blocker that works by relaxing blood vessels and slowing heart rate to improve blood flow and decrease blood pressure[8]. - Amlopin, which is a brand name for amlodipine, a calcium channel blocker that lowers blood pressure by relaxing the smooth muscle in the vessel walls, allowing easier blood flow and reducing cardiac workload[3][4]. The combination of these two agents provides an additive antihypertensive effect by targeting different mechanisms involved in regulating vascular tone and cardiac output. This dual approach helps achieve better control of high blood pressure than either agent alone.

Brand names
Monorova + Amlopin
02

Targets

CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)ADRB1 (β1)

Beyond the preview

Go deeper on Monorova + Amlopin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Monorova + Amlopin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call